For the Inventor, By the Inventor

Enter inventor name

Vancouver, Canada

Steven S Plotkin

USPTO Granted Patents = 12 (Patent Applications = 11)

CIPO Patents = 1 (Patent Applications = 9)

EPO Patents = 2 (Patent Applications = 12)

Average Co-Inventor Count = 2.3

ph-index = 1

Forward Citations = 3(Granted Patents)

Company Filing History:

University of British Columbia

Promis Neurosciences Inc.

where one patent can have more than one assignee

Years Active: 2019-2025

Loading Chart...

Loading Chart...

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12404321 - Conformation-specific epitopes in alpha-synuclein, antibodies thereto and methods related thereof (2025-09-02),

2. 12286469 - Humanized antibodies binding to amyloid-beta (A-beta) (2025-04-29),

3. 12173055 - N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto (2024-12-24),

4. 12071472 - Methods of reducing toxicity induced by Amyloid beta (A-beta) oligomers using antibodies specific to A-beta oligomers (2024-08-27),

5. 11970522 - Cyclic compound/peptide comprising an A-beta15-18 peptide and a linker that is covalently coupled to the n-terminus residue and the c-terminus residue of the A-BETA15-18 peptide (2024-04-30),

6. 11905318 - Cyclic compound/peptide comprising an A-beta13-16 peptide and a linker that is covalently coupled to the n-terminus residue and the c-terminus residue of the A-beta13-16 peptide (2024-02-20),

7. 11756650 - Systems and methods for predicting misfolded protein epitopes by collective coordinate biasing (2023-09-12),

8. 11214613 - Epitopes in the RNA recognition motif 1 (RRM1) of TDP-43 and misfolding-selective antibodies thereto (2022-01-04),

9. 10774120 - Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide (2020-09-15),

10. 10772969 - N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto (2020-09-15),

11. 10759837 - Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide (2020-09-01),

12. 10475525 - Methods and systems for predicting misfolded protein epitopes (2019-11-12),

Title: The Innovations of Steven S. Plotkin

Introduction

Steven S. Plotkin is a prominent inventor based in Vancouver, Canada, known for his significant contributions to the field of neuroscience. With a total of 12 patents to his name, he has made remarkable strides in understanding and addressing neurodegenerative diseases.

Latest Patents

Among his latest patents is the invention related to conformation-specific epitopes in alpha-synuclein, which focuses on antibodies that selectively recognize misfolded oligomeric alpha-synuclein. This innovation is crucial as it aims to inhibit alpha-synuclein propagation and toxicity. Another notable patent involves humanized antibodies binding to amyloid-beta (A-beta), which includes methods for creating and utilizing these antibodies. These advancements highlight his commitment to developing therapeutic solutions for complex neurological conditions.

Career Highlights

Steven has worked with esteemed institutions such as the University of British Columbia and Promis Neurosciences Inc. His work in these organizations has allowed him to push the boundaries of research and innovation in the field of neuroscience.

Collaborations

Throughout his career, Steven has collaborated with notable professionals, including Neil R. Cashman and Johanne Kaplan. These partnerships have contributed to the advancement of his research and the development of his patents.

Conclusion

Steven S. Plotkin's contributions to neuroscience through his patents and collaborations underscore his role as a leading inventor in the field. His work continues to pave the way for innovative solutions to neurodegenerative diseases.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…